ARTEROprotect® is a two-compo0nent dietary supplement containing the following ingredients:
- Vitamin K2-MK7
In time, the majority of persons develop calcium deposits in main arteries. Vascular calcification reduces the aortal elasticity thus compromising the structural identity of the blood vessel. This compromises cardiovascular hemodynamics and increases the risk of hypertension, arterial stenosis, ischemic heart disease, ischemia of the brain and lower limbs. Therefore, prevention and/or reduction of arterial calcification can improve the outcome of disease.
Numerous studies including thousands of subjects have shown that coronary calcification is a strong and independent predictor of the coronary heart disease. The risk of instable angina, myocardial infarction and sudden death is significantly increased with the increase of the degree of coronary arteries calcification.
It is the established fact that vitamin K1 has an important role in the synthesis of the coagulation factor. Namely, it is a co-factor of the vitamin K-dependent carboxylase enzyme, which carboxylates the flutamic moiety of those proteins, thus bringing them to the functional state.
Vitamin K2-MK7 has recently attracted a lot of attention. It is suggested that this form of vitamin K is in particular important for the prevention of osteoporosis and blood vessel calcification.
Vitamin K2-MK7 is essential for the synthesis of the matrix gla protein (MGP) in the smooth muscles of blood vessels and cartilage. It is believed that this protein is a strong inhibitor of blood vessel calcification.
Vitamin K2-MK7 deficiency increases the level of under-carboxylated MGP, which is not functional, leading to the increased depositing of calcium in blood vessels.
A large number of studies have shown that the increased intake of vitamin K2-MK7 reduces blood vessel calcification and the incidence of coronary heart disease and cardiovascular diseases in general. The studies conducted so far provide evidence that vitamin K2-MK7 could to prevent arterial calcification. Not only that, but it has been demonstrated that vitamin K2-MK7 can lead to calcification regression and increase blood vessel elasticity.
A clinical study currently under way includes 244 participants. It is a randomized, double-blind, placebo-controlled study of the effect of vitamin K2-MK7 on the health of the cardiovascular system. The patients are supplemented with 180 µg of vitamin K2-MK7 daily for the period of 3 years. Vitamin K2-MK7 not only prevented stiffening, it also resulted in an unprecedented statistically significant improvement of vascular elasticity both mesured with ultrasound techniques and pulse wave velocity.
The improvement of the following measured parameters has been observed:
– improved characteristics of the carotid artery
– improved Young’s module of elasticity
– significantly reduced pulse rate wave.
The results show that vitamin K2-MK7:
– leads to significant improvement of blood vessels condition.
– prevents blood vessel damage.
– improves blood vessel elasticity.
Cardiovascular diseases (CVD) are the leading causes of morbidity and mortality in modern man. The World Health Organization estimates that more than 7 million people die of heart disease every year. Three major risk factors for CVD are high lipids (cholesterol), smoking and hypertension. It is estimated that about 75% of all cardiovascular disease in the world are results of these factors. Disorders of lipid metabolism are fundamental for atherosclerosis development. They are often associated with diabetes, obesity and hypertension, which act synergistically, leading to arteriosclerotic changes.
Large number of studies showed that 20 mg of octacosanol decreases:
– total cholesterol levels (23%)
– LDL cholesterol levels (27.5%)
– LDL to HDL cholesterol ratio (38.3%)
– total cholesterol to HDL-C ratio (30.5%).
Of specific interest is the ability of octacosanol to increase HDL-C, which has been observed consistently in several studies. The cholesterol lowering effects of policosanol are dose dependent. The reduction of LDL-C, total cholesterol, LDL-C to HDL-C, and total cholesterol to HDL-C ratios showed a dependence on the successive dose increases. Further increasing the dose to 40 mg octacosanol has no additional effect on lipid profile compared to 20 mg, but has significant effect on triglycerides reduction. The ratios of total or LDL cholesterol to HDL-C are considered important parameters to characterize beneficial effects on lipid profiles in terms of cardiovascular risk. In this respect, octacosanol seems to be superior to both statins and fibrates.
Several randomized, double blind placebo controlled studies showed that 20 mg of octacosanol inhibits induced platelet aggregation. The mechanism of antiaggregatory effect was due to the inhibition of arachidonic acid metabolism, at the stage where tromboxan A2 is formed. In addition, it was sown that 20 mg of octacosanol daily is as effective as 100 mg of acetylsalicylic acid.
During long-term administration, octacosanol is generally well tolerated and safe, causing no adverse clinical or biochemical effects, such as increase in transaminase or creatin kinase. Long-term studies performed over a 1-year period showed that the total and LDL cholesterol-lowering effects are maintained throughout this time period and that the maximal effects are reached after 6 to 8 weeks of treatment.
The beneficial effect of octacosanol on lipid profile was observed in special patient populations. So far it was investigated patients with non-insulin-dependent diabetes mellitus; hypertension, hepatic dysfunction, patients with 2 or more additional CHD risk factors, postmenopausal women. It is particularly important that no clinical and laboratory adverse event or drug interactions was observed in this special population, where impairment in renal and hepatic function, multiple medication intake, and concomitant diseases are usually present.